• Home
  • Chongqing Sintaho Pharmaceutical Co., Ltd.

Chongqing Sintaho Pharmaceutical Co., Ltd.

About Chongqing Sintaho Pharmaceutical Co., Ltd.

FDA-inspected facility 

Leveraging its platforms of high-potency small molecules, XDC components and polypeptides, Sintaho supplies chemical synthesis APIs for oncology, metabolism and nervous system therapeutic areas to proprietary, generic drug companies and the signatory customers.

Sintaho is harnessing our expertise and collective passion to s...

Read more Show less
Certifications
  • CE
    CE
  • FDA
    FDA
  • GMP
    GMP
  • ISO
    ISO
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    China
  • On CPHI since:
    2023
  • Certificates:
    4
  • Employees:
    250 - 499
Company types
CMO/CDMO
Contract Service
Pharmaceutical company
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Contact info
Show contact info Hide contact info

Products from Chongqing Sintaho Pharmaceutical Co., Ltd. (3)

  • Eribulin Mesylate

    Product Eribulin Mesylate

    Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
  • Deruxtecan

    Product Deruxtecan

    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
  • Exatecan Mesylate

    Product Exatecan Mesylate

    Exatecan mesylate (DX8951f) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research.